Job Trends
Rampart Bioscience was working on a platform to deliver gene therapies without the need for viral vectors.
Labor Market Reports
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities during the second quarter of 2025, with increased pressure from further layoffs.
Establishing trust through thought leadership is no longer optional in today’s cautious biopharma market. Learn how strategic insights and targeted outreach can turn awareness into high-converting leads.
Now Hiring
Looking for a new opportunity in New Jersey? These nine companies have open roles that could be a great fit for you.
Job listings in the area have ticked up in the last month. These seven companies are hiring in South San Francisco right now, including scientist and clinical roles.
Looking for a biopharma job in New York? Check out the BioSpace list of eight companies hiring life sciences professionals like you.
Career Advice
Clarity on employment terms is essential to protect careers. In this column, Kaye/Bassman’s Michael Pietrack speaks to employment attorney Howard Matalon, JD, partner at OlenderFeldman, on how to evaluate the fine print of an employment agreement.
THE LATEST
Medical device firm Caisson Interventional LLC plans to expand its Maple Grove facilities by 30,000 square foot and add 50 jobs.
This biotech could potentially be a better value.
Visterra has outgrown its headquarters and is moving to a site double the size in suburban Waltham, MA.
Along with lampalizumab, Roche announced it was culling several drug programs in its latest financial filing.
This is a market like the world has never seen.
AbbVie provided an unexpectedly strong 2018 guidance revision, largely built on the new corporate tax rate.
The FDA’s Breakthrough Therapy Designation for balovaptan was primarily based on efficacy findings in the VANILLA study, a Phase II trial of balovaptan in adults with ASD.
Only a week after Sanofi ponied up $11.6B to buy Waltham, Massachusetts-based Bioverativ, the French drugmaker is buying Ghent, Belgium-based Ablynx for $4.8B.
Sanofi has announced major restructuring, which will involve about 400 job cuts in the U.S.
Amgen’s migraine drug Aimovig continues to impress with its efficacy in late-stage studies.